Vertex stock jumps. What Wall Street is saying about its kidney drug trial.

The drug maker says its treatment of a rare kidney disease met its main goal in a late-stage trial.

Is Vertex Pharmaceuticals (VRTX) Still Fairly Priced After Recent Share Price Weakness

If you are wondering whether Vertex Pharmaceuticals at around US$460 per share still lines up with its fundamentals, you are not alone. This article is here to unpack what that price might imply. The ...
pharmaphorum

Vertex preps FDA filing for IgAN drug after phase 3 readout

Interim results from RAINIER reveal that an 80 mg dose of povetacicept every four weeks delivered a 52% reduction in protein ...

Vertex passes key test in quest to treat kidney diseases

Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial.
BioSpace

Vertex’s Nephropathy Asset Delivers ‘Strong’ Late-Stage Data, Clears Path to FDA

Vertex Pharmaceuticals has a rolling biologics license application with the FDA for povetaciceptin IgA nephropathy. With new data from RAINIER, the biotech expects to complete its submission by the ...
Seeking Alpha

Vertex: Continuing To Dominate In CF, But What About Its Pain Pipeline?

Vertex Pharmaceuticals Incorporated remains a buy despite recent share price weakness, supported by its dominant cystic fibrosis franchise and robust late-stage pipeline. Alyftrek's launch extends ...
Nasdaq

Vertex Pharmaceuticals's Options: A Look at What the Big Money is Thinking

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals. Looking at options history for Vertex Pharmaceuticals (NASDAQ:VRTX) we detected 11 trades. If we ...
AOL

What's Wrong With Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals (NASDAQ: VRTX) has been a top pharma stock in recent years. It has been generating strong revenue growth while also building out its portfolio of drugs, expanding its growth ...